Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | -9.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EBITDA | -201.45M | -177.77M | -84.66M | -31.48M | 0.00 | 0.00 |
Net Income | -188.51M | -177.81M | -71.90M | -29.80M | -19.41M | -3.43M |
Balance Sheet | ||||||
Total Assets | 354.94M | 205.90M | 251.64M | 114.44M | 11.13M | 1.49M |
Cash, Cash Equivalents and Short-Term Investments | 165.01M | 198.19M | 236.57M | 110.11M | 10.61M | 1.41M |
Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.50M |
Total Liabilities | 13.39M | 14.65M | 10.48M | 166.71M | 34.05M | 5.08M |
Stockholders Equity | 341.56M | 191.26M | 241.15M | -52.27M | -22.93M | -3.60M |
Cash Flow | ||||||
Free Cash Flow | -192.70M | -166.41M | -81.17M | -29.22M | -14.56M | -2.46M |
Operating Cash Flow | -192.66M | -166.31M | -81.17M | -29.22M | -14.56M | -2.46M |
Investing Cash Flow | 78.03M | 114.96M | -160.47M | -21.76M | 0.00 | 0.00 |
Financing Cash Flow | 189.22M | 116.14M | 203.25M | 128.02M | 23.81M | 3.83M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
56 Neutral | $732.66M | ― | -44.59% | ― | -73.79% | -5.24% | |
53 Neutral | $909.20M | ― | -56.31% | ― | ― | -106.10% | |
46 Neutral | C$198.48M | -3.49 | -23.22% | 2.62% | 21.07% | -1.26% | |
43 Neutral | $942.12M | 2.31 | -50.47% | ― | -100.00% | 94.68% | |
42 Neutral | $1.49B | ― | -69.30% | ― | ― | -68.13% | |
36 Underperform | $1.16B | ― | -31.30% | ― | ― | 12.85% |
On March 29, 2025, Mineralys Therapeutics announced detailed results from the Advance-HTN pivotal trial of lorundrostat for uncontrolled and resistant hypertension. The trial demonstrated significant blood pressure reductions and a favorable safety profile, underscoring lorundrostat’s potential as a best-in-class treatment for high-risk patients. The results were presented at the American College of Cardiology’s Annual Scientific Session & Expo, highlighting lorundrostat’s clinical utility across diverse care settings and its potential impact on hypertension care.
On March 10, 2025, Mineralys Therapeutics announced positive results from its pivotal Launch-HTN Phase 3 and Advance-HTN Phase 2 trials for lorundrostat, a treatment for uncontrolled or resistant hypertension. Both trials met their primary efficacy endpoints, showing statistically significant reductions in systolic blood pressure and a favorable safety profile, indicating potential for regulatory approval and commercial value.